GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA

March 17, 2014 | About:
GuruFocus

GuruFocus

353 followers

According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:

Calamos Asset Management Inc. (CLMS): Chairman, CEO and Global Co-CIO, 10% Owner John P. Calamos Sr. Bought 225,004 Shares

Chairman, CEO and Global Co-CIO, 10% Owner of Calamos Asset Management Inc. (CLMS) John P. Calamos Sr. bought 225,004 shares during the past week at an average price of $12.64. Calamos Asset Management Inc. is a global asset management firm that offers strategies to fulfill a range of asset allocation goals through a multi-team platform. Calamos Asset Management Inc. has a market cap of $259.508 million; its shares were traded at around $12.64 with a P/E ratio of 21.10 and P/S ratio of 0.94. The dividend yield of Calamos Asset Management Inc. stocks is 3.96%.

Mario Gabelli (Trades, Portfolio) owns 126,000 shares as of 12/31/2013, which accounts for 0.008% of the $18.65 billion portfolio of GAMCO Investors.

SVP and CFO Nimish S. Bhatt bought 337 shares of CLMS stock on 02/25/2014 at the average price of $11.45. Nimish S. Bhatt owns at least 88,689 shares after this. The price of the stock has increased by 10.39% since.

Opko Health Inc. (OPK): CEO & Chairman, 10% Owner Phillip Frost Md Et Al Bought 123,500 Shares

CEO and Chairman, 10% Owner of Opko Health Inc. (OPK) Phillip Frost Md Et Al bought 123,500 shares during the past week at an average price of $9.66. Opko Health Inc. was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics Inc. Opko Health Inc. has a market cap of $3.99 billion; its shares were traded at around $9.66 with and P/S ratio of 34.50. Opko Health Inc. had an annual average earnings growth of 4.40% over the past 10 years.

Opko recently reported its fourth quarter and full year 2013 financial results. For the fourth quarter of 2013, consolidated revenues increased about 30% to $20.7 million from $16.2 million in the prior year period. For the year ended Dec. 31, 2013, consolidated revenues more than doubled to $96.5 million from $47.0 million in the prior year.

George Soros (Trades, Portfolio) owns 844,600 shares as of 12/31/2013, an increase of 13.37% from the previous quarter. This position accounts for 0.061% of the $11.78 billion portfolio of Soros Fund Management LLC. Mario Gabelli (Trades, Portfolio) owns 15,000 shares as of 12/31/2013, which accounts for 0.0007% of the $18.65 billion portfolio of GAMCO Investors.

Vice Chairman and CTO Jane Hsiao Ph.D. bought 10,000 shares of OPK stock on 01/30/2014 at the average price of $8.14. Jane Ph D Hsiao owns at least 36,818,758 shares after this. The price of the stock has increased by 18.67% since.

OvaScience Inc. (OVAS): President and CEO, 10% Owner Michelle Dipp Bought 100,000 Shares

President and CEO, 10% Owner of OvaScience Inc. (OVAS) Michelle Dipp bought 100,000 shares on 03/07/2014 at an average price of $10.26. OvaScience Inc. was established in 2011 & is based in Cambridge, Mass. Ovascience Inc. has a market cap of $190.459 million.

OvaScience recently reported its fourth quarter 2013 financial results. Net loss for the three months ended Dec. 31, 2013 was $11.0 million, or ($0.64) per share, as compared to net loss of $4.2 million, or ($0.33) per share, for the three months ended Dec. 31, 2012.

Director, 10% Owner Christoph H. Westphal bought 100,000 shares of OVAS stock on 03/07/2014 at the average price of $10. Christoph H. Westphal owns at least 4,527,348 shares after this. The price of the stock has increased by 2.6% since.

Retrophin Inc. (RTRX): CEO, 10% Owner Martin Shkreli Bought 40,658 Shares

CEO, 10% Owner of Retrophin Inc. (RTRX) Martin Shkreli bought 40,658 shares during the past week at an average price of $17.35. Pivotal Therapeutics Inc. is engaged in the development of pharmaceutical products for the treatment of rare diseases. Retrophin Inc. has a market cap of $402.44 million; its shares were traded at around $17.35 .

Director Cornelius E. Golding bought 3,000 shares of RTRX stock on 12/24/2013 at the average price of $7.5. Cornelius E. Golding owns at least 3,000 shares after this.

MDC Partners Inc. (MDCA): Chairman, CEO and President, 10% Owner Miles Nadal Bought 30,000 Shares

Chairman, CEO and President, 10% Owner of MDC Partners Inc. (MDCA) Miles Nadal bought 30,000 shares during the past week at an average price of $21.17. MDC Partners Inc. was formed by Certificate of Amalgamation effective Dec. 19, 1986, pursuant to the Business Corporations Act (Ontario). MDC Partners Inc. has a market cap of $1.06 billion; its shares were traded at around $21.17 with and P/S ratio of 0.88. The dividend yield of MDC Partners Inc. stocks is 3.02%.

Joel Greenblatt (Trades, Portfolio) owns 18,416 shares as of 12/31/2013, an increase of 63.73% from the previous quarter. This position accounts for 0.011% of the $4.2 billion portfolio of Gotham Capital. Mario Gabelli (Trades, Portfolio) owns 16,500 shares as of 12/31/2013, which accounts for 0.0023% of the $18.65 billion portfolio of GAMCO Investors.

CFO David B. Doft bought 1,000 shares of MDCA stock on 03/12/2014 at the average price of $21.5. David B. Doft owns at least 163,619 shares after this. The price of the stock has decreased by 1.53% since.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK